Orion’s pharmaceutical innovations are created within its R&D organisation. The organisation employs top professionals in the field of drug molecule development and optimisation.
A Review article summarizing the Potential of Levosimendan in the Management of ALS: Overview of a Working Hypothesis
The Phase 2 clinical trial (LEVALS) show encouraging results: in 66 patients supine SVC was significantly higher after 14 days treatment on oral levosimendan compared to placebo.
Orion develops new pharmaceuticals in three therapy areas. Orion’s pharmaceutical R&D focuses on the central nervous system, cancer and critical care, and inhalable Easyhaler® pulmonary drugs. Orion also develops veterinary and generic drugs.
A list of recent posters presented at congresses and articles published in peer reviewed scientific journals.
What does it take to develop a new medicine? To start with, you need a dedicated team of top scientists and other professionals. The journey might take up to fifteen years. Take a look!
Our aim is to work in accordance with the requirements, standards and ethical codes of our industry in our pharmaceutical research and development activities too. Our R&D Policy highlights how we make sure that our practices are on an ethically sustainable basis.
Partnerships and networking are important for Orion throughout the entire value chain of operations. We collaborate with other companies in research and development, manufacturing and marketing of products internationally.